← 返回

三级淋巴结构:抗癌治疗的潜在生物标志物

英文原题:Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy.

查看英文原题

Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy.

PubMed 2022/12/02(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

三级淋巴结构(TLS)是免疫微环境中的一种特殊组分,主要由TIL(肿瘤浸润淋巴细胞)组成,包括T细胞、B细胞、DC细胞和高内皮微静脉(HEV)。对于癌症患者,免疫微环境的评估对肿瘤生物学行为、治疗方法和预后具有预测作用。因此,TLS作为一种新的潜在生物标志物开始受到研究者的关注。然而,TLS的组成和机制仍不清楚,临床检测方法仍在探索中。尽管在临床试验中已取得一些有意义的结果,但此类方法应用于临床实践仍有很长的路要走。然而,我们相信随着基础研究和临床试验的不断进展,TLS检测及相关治疗能够惠及越来越多的患者。在本综述中,我们概括了TLS的定义和组成,根据治疗方法总结了涉及TLS的临床试验,并描述了诱导TLS形成的可能方法。

展开英文摘要原文

A tertiary lymphoid structure (TLS) is a special component in the immune microenvironment that is mainly composed of tumor-infiltrating lymphocytes (TILs), including T cells, B cells, DC cells, and high endothelial venules (HEVs). For cancer patients, evaluation of the immune microenvironment has a predictive effect on tumor biological behavior, treatment methods, and prognosis. As a result, TLSs have begun to attract the attention of researchers as a new potential biomarker.

However, the composition and mechanisms of TLSs are still unclear, and clinical detection methods are still being explored. Although some meaningful results have been obtained in clinical trials, there is still a long way to go before such methods can be applied in clinical practice.

However, we believe that with the continuous progress of basic research and clinical trials, TLS detection and related treatment can benefit more and more patients. In this review, we generalize the definition and composition of TLSs, summarize clinical trials involving TLSs according to treatment methods, and describe possible methods of inducing TLS formation.

论文信息

作者
Zou J、Zhang Y、Zeng Y、Peng Y、Liu J、Xiao C、Wu F
单位
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.China
文献类型
综述
期刊
Cancers2022 Dec 2
原文标识
PubMed 36497450 · DOI 10.3390/cancers14235968